You're signed outSign in or to get full access.
About
Xinzhe Fang is an Associate at RA Capital Management based in Boston, MA. He operates within RA Capital's TechAtlas division, focusing on supporting investment research, due diligence, and strategic assessment for life sciences and biotechnology companies. His role involves analyzing therapeutic areas, technology platforms, and market trends to inform investment decisions across biotech and healthcare sectors.
Prior to joining RA Capital, Xinzhe gained experience as Associate Director of Business Development at Inmagene Biopharmaceuticals, where he contributed to business strategy and partnership development in the pharmaceutical and biotech fields. He has also held a summer internship at RA Capital, reinforcing his expertise in biotech investment and due diligence processes.
Xinzhe holds an MBA from the Tuck School of Business at Dartmouth, an MPhil in Biochemistry from the University of Cambridge, and dual BSc degrees in Biological Sciences from Fudan University and the University of Birmingham. His strong scientific background and commercial acumen uniquely position him to assess investment opportunities in the biotech and pharmaceutical sectors.
Career History
| Organization | Role | Date Range | Details |
|---|---|---|---|
| RA Capital Management | Associate | Jul 2024 to Present | — |
| RA Capital Management, L.P. | Summer Intern | Jun 2023 to Aug 2023 | — |
| Inmagene Biopharmaceuticals 创响生物 | Associate Director Business Development | Mar 2022 to Sep 2022 | - Supported the signing of 3 in-license deals ($1.6 Bn deal size) in immunology/inflammatory diseases - Led BD activities including search & evaluation and due diligence - Supported Series C financing... |
| Inmagene Biopharmaceuticals | Senior Business Development Manager | Nov 2020 to Mar 2022 | — |
| Sperogenix 曙方医药 | Senior Business Development Manager | Feb 2020 to Aug 2020 | Led the signing of an in-licencing deal with Minoryx Therapeutics for leriglitazone in X-ALD. |
| Sanofi | Strategic Planning Manager | Aug 2018 to Feb 2020 | New product planning for all rare disease and rare blood disorders pipeline products, including Aldurazyme, Nexviazyme, Xenpozyme, Enjaymo, Cablivi, BIVV001, fitusiran, etc. |
| ZS | Associate Consultant | Jan 2018 to Jul 2018 | — |
| ZS | Business Analyst | Jun 2015 to Dec 2017 | — |
Education
The Tuck School of Business at Dartmouth
Master of Business Administration - MBA
2022 — 2024
University of Cambridge
Master of Philosophy (MPhil), Biochemistry
2013 — 2014
Fudan University
Bachelor of Science (BS), Biology/Biological Sciences, General
2009 — 2013
The University of Birmingham
Bachelor of Science (BSc), Biology/Biological Sciences, General
2011 — 2013
Others at Ra Capital Management, L.P. (41)
| Name | Role | Location |
|---|---|---|
 | Associate | Boston, MA , United States |
A Alexander Becker | Senior Associate | Boston, MA , United States |
 | Associate | Cambridge, MA , United States |
 | Associate | Boston, MA , United States |
 | Principal | New York, NY , United States |
| Associate | Boston, MA , United States | |
B Brian L | Analyst | Boston, MA , United States |
 | Principal | San Francisco, CA , United States |
D David Migl | Analyst | United States |
F Fuad Naser | Analyst | Boston, MA , United States |
Similar Fund Managers
| Name | Role | Fund | Location |
|---|---|---|---|
J John Brennan | Principal | Sirios Capital Management L P | Boston, MA , United States |
K Kristin Foley | Head of Trading | Sirios Capital Management L P | Boston, MA , United States |
